

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than October 31, 2000.

A. Federal Reserve Bank of Dallas
(W. Arthur Tribble, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Gene Allen Van Meter*, Beaumont, Texas; *Barbara Van Meter*, Beaumont, Texas; *Gene Allen Van Meter, Jr.*, Lumberton, Texas; and *Gary Stephen Van Meter*, Beaumont, Texas all to acquire additional voting shares of *Lamar Bancshares, Inc.*, Beaumont, Texas, and thereby indirectly acquire additional voting shares of *Lamar Bank*, Beaumont, Texas.

Board of Governors of the Federal Reserve System, October 11, 2000.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 00-26542 Filed 10-16-00; 8:45 am]

BILLING CODE 6210-01-P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies; Correction

This notice corrects a notice (FR Doc. 00-25132) published on page 58771 of the issue for Monday, October 2, 2000.

Under the Federal Reserve Bank of Kansas City heading, the entry for *Sturm Financial Group, Inc.*, Denver, Colorado, is revised to read as follows:

A. Federal Reserve Bank of Kansas City (D. Michael Manies, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. *Sturm Financial Group, Inc.*, Denver, Colorado; to become a bank holding company by acquiring 100 percent of the voting shares of *Sturm*

Banks of Colorado, Inc., Denver, Colorado, and thereby indirectly acquire *Bank of Cherry Creek N.A.*, Boulder, Colorado, *Bank of Cherry Creek N.A.*, Denver, Colorado, *Mesa National Bank*, Grand Junction, Colorado, *Western National Bank of Colorado*, Colorado Springs, Colorado; *Sturm Banks of Wyoming, Inc.*, Denver, Colorado, and thereby indirectly acquire *American National Bank of Cheyenne*, Cheyenne, Wyoming, *Wyoming Bank & Trust Company N.A.*, Buffalo, Wyoming, *Stockgrowers State Bank N.A.*, Worland, Wyoming, *Bank of Laramie N.A.*, Laramie, Wyoming; and *Sturm Banks of Kansas City, Inc.*, Denver, Colorado, and thereby indirectly acquire *Premier Bank*, Lenexa, Kansas.

In connection with this application, Applicant also has applied to acquire *Community First Data Services, Inc.*, Cheyenne, Wyoming, and thereby engage in data processing activities, pursuant to 225.28(b)(14) of Regulation Y.

In addition to this application, *Sturm Financial Group, Inc.*, Denver, Colorado and *Sturm Banks of Kansas City, Inc.*, Denver, Colorado also have applied to engage in lending activities, pursuant to 225.28(b)(1) of Regulation Y.

Comments on this application must be received by October 26, 2000.

Board of Governors of the Federal Reserve System, October 11, 2000.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 00-26541 Filed 10-16-00; 8:45 am]

BILLING CODE 6210-01-P

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 11 a.m., Monday, October 23, 2000.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202-452-3204.

SUPPLEMENTARY INFORMATION: You may call 202-452-3206 beginning at

approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: October 13, 2000.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 00-26784 Filed 10-13-00; 3:25 pm]

BILLING CODE 6210-01-P

FEDERAL TRADE COMMISSION

Agency Information Collection Activities; Proposed Collection; Comment Request

AGENCY: Federal Trade Commission (FTC).

ACTION: Notice.

SUMMARY: The FTC has investigated several cases in which manufacturers of pharmaceutical drug products and generic competitors have allegedly entered into anticompetitive agreements to delay generic entry. These cases may foreshadow similar anticompetitive agreements that may eliminate the benefits to consumers of generic drug competition. The FTC is considering a study to investigate how generic drug competition has developed in light of certain provisions in the Hatch-Waxman Act that govern entry of generic drug products. Before investigating whether these provisions of the Hatch-Waxman Act encourage generic competition or facilitate the use of anticompetitive strategies, the FTC seeks public comments on its proposed information requests to firms in the pharmaceutical drug industry. Comments will be considered before the FTC submits a request for Office of Management and Budget (OMB) review under the Paperwork Reduction Act.

DATES: Comments must be submitted on or before December 18, 2000.

ADDRESSES: Send written comments to Secretary, Federal Trade Commission, Room H-159, 600 Pennsylvania Avenue, NW., Washington, DC 20580, or by e-mail to genericdrugstudy@ftc.gov. The submissions should include the submitter's name, address, telephone number, and, if available, FAX number and e-mail address. All submissions should be captioned "Generic Drug Study—FTC File No. V000014."